Association of DNMT1 gene polymorphisms in exons with sporadic infiltrating ductal breast carcinoma among chinese han women in the heilongjiang province

Clinical Breast Cancer

Volumn 10, Issue 5, 2010, Pages 373-377

  Xiang, Gao ^a   Zhenkun, Fu ^a   Shuang, Chen ^a   Jie, Zhang ^a   Hua, Zhang ^a   Wei, Jiang ^a   Da, Pang ^a   Dianjun, Li ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

DNA methyltransferase 1; Haplotype; Infiltrating ductal carcinoma; Single nucleotide polymorphism

Indexed keywords

DNA METHYLTRANSFERASE 1; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; CHINA; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; DNA POLYMORPHISM; EXON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUMOR VOLUME;

EID: 77957808708     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.049     Document Type: Article

References (26)

1. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study iden-tifies novel breast cancer susceptibility loci. Nature 2007; 447:1087-93.
2. Feng W, Shen L, Wen S, et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 2007; 9:R57.
3. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001; 293:1068-70.
4. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992; 69:915-26.
5. Lee SJ, Jeon HS, Jang JS, et al. DNMT3B polymorphisms and risk of primary lung cancer. Carcinogenesis 2005; 26:403-9.
6. Jones JS, Amos CI, Pande M, et al. DNMT3b polymorphism and hereditary non-polyposis colorectal cancer age of onset. Cancer Epidemiol Biomarkers Prev 2006; 15:886-91.
7. Kanai Y, Ushijima S, Nakanishi Y, et al. Mutation of the DNA methyltransferase (DNMT) 1 gene in human colorectal cancers. Cancer Lett 2003; 192:75-82.
8. Robertson KD, Uzvolgyi E, Liang G, et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and over-expression in tumors. Nucleic Acids Res 1999; 27:2291-8.
9. Bestor TH. Activation of mammalian DNA methyltransferase by cleavage of a Zn binding regulatory domain. EMBO J 1992; 11:2611-7.
10. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mam-malian DNA (cytosine-5) methyltransferases. Nat Genet 1998; 19:219-20.
11. Milutinovic S, Brown SE, Zhuang Q, et al. DNA methyltransferase 1 knock down induces gene expression by a mechanism independent of DNA methylation and histone deacetylation. J Biol Chem 2004; 279:27915-27.
12. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene 2001; 20:3139-55.
13. Park BL, Kim LH, Shin HD, et al. Association analyses of DNA methyltransfer-ase-1 (DNMT1) polymorphisms with systemic lupus erythematosus. J Hum Genet 2004; 49:642-6.
14. Hermann A, Goyal R, Jeltsch A. The Dnmt1 DNA-(cytosine-C5)- methyltransfer-ase methylates DNA processively with high preference for hemimethylated target sites. J Biol Chem 2004; 279:48350-9.
15. Howell CY, Bestor TH, Ding F, et al. Genomic imprinting disrupted by a maternal effect mutation in the Dnmt1 gene. Cell 2001; 104:829-38.
16. Taylor J, Moore H, Beaujean N, et al. Cloning and expression of sheep DNA methyltransferase 1 and its development-specific isoform. Mol Reprod Dev 2009; 76:501-13.
17. Chen T, Hevi S, Gay F, et al. Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells. Nat Genet 2007; 39:391-6.
18. Wjst M. Target SNP selection in complex disease association studies. BMC Bioin-formatics 2004; 5:92.
19. Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet 2000; 9:2395-402.
20. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315:525-8.
21. Elledge RM, Green S, Puge R, et al. Estrogen receptor(ER) and progesterone receptor (PR), by ligand-binding assay compared with ER, PR and pS2, by im-muno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000; 89:111-7.
22. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109:1721-8.
23. Stendahl M, Ryden L, Nordenskjold B, et al. High progesterone receptor expres-sion correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 2006; 12:4614-8.
24. Beenken SW, Grizzle WE, Crowe DR, et al. Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53. Ann Surg 2001; 233:630-8.
25. Rudolph P, Alm P, Olsson H, et al. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. Hum Pathol 2001; 32:311-9.
26. Leng S, Stidley CA, Bernauer AM, et al. Haplotypes of DNMT1 and DNMT3B are associated with mutagen sensitivity induced by benzo[a]pyrene diol epoxide among smokers. Carcinogenesis 2008; 29:1380-5.